These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 21871246)

  • 1. Late relapses following high-dose autologous stem cell transplantation (HD-ASCT) for Hodgkin's lymphoma (HL) in the ABVD therapeutic era.
    Keller SF; Kelly JL; Sensenig E; Andreozzi J; Oliva J; Rich L; Constine L; Becker M; Phillips G; Liesveld J; Fisher RI; Bernstein SH; Friedberg JW
    Biol Blood Marrow Transplant; 2012 Apr; 18(4):640-7. PubMed ID: 21871246
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
    Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
    Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined ifosfamide, etoposide and oxalipatin chemotherapy, a low-toxicity regimen for first-relapsed or refractory Hodgkin lymphoma after ABVD/EBVP: a prospective monocentre study on 34 patients.
    Sibon D; Ertault M; Al Nawakil C; de Bazelaire C; Franchi P; Brière J; de Kerviler E; Beranger N; Thieblemont C; Brice P
    Br J Haematol; 2011 Apr; 153(2):191-8. PubMed ID: 21385169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose cyclophosphamide, carmustine (BCNU), and etoposide (VP16-213) with or without cisplatin (CBV +/- P) and autologous transplantation for patients with Hodgkin's disease who fail to enter a complete remission after combination chemotherapy.
    Reece DE; Barnett MJ; Shepherd JD; Hogge DE; Klasa RJ; Nantel SH; Sutherland HJ; Klingemann HG; Fairey RN; Voss NJ
    Blood; 1995 Jul; 86(2):451-6. PubMed ID: 7541661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ifosfamide, idarubicin, and etoposide in relapsed/refractory Hodgkin disease or non-Hodgkin lymphoma: a salvage regimen with high response rates before autologous stem cell transplantation.
    Oyan B; Koc Y; Ozdemir E; Kars A; Turker A; Tekuzman G; Kansu E
    Biol Blood Marrow Transplant; 2005 Sep; 11(9):688-97. PubMed ID: 16125639
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
    Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
    Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose thiotepa, etoposide and carboplatin as conditioning regimen for autologous stem cell transplantation in patients with high-risk Hodgkin's lymphoma.
    Di Ianni M; Ballanti S; Iodice G; Reale A; Falzetti F; Minelli O; Serio G; Martelli MF; Dammacco F; Vacca A; Ria R
    Hematology; 2012 Jan; 17(1):23-7. PubMed ID: 22549444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
    Viviani S; Zinzani PL; Rambaldi A; Brusamolino E; Levis A; Bonfante V; Vitolo U; Pulsoni A; Liberati AM; Specchia G; Valagussa P; Rossi A; Zaja F; Pogliani EM; Pregno P; Gotti M; Gallamini A; Rota Scalabrini D; Bonadonna G; Gianni AM; ; ;
    N Engl J Med; 2011 Jul; 365(3):203-12. PubMed ID: 21774708
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
    Sirohi B; Cunningham D; Powles R; Murphy F; Arkenau T; Norman A; Oates J; Wotherspoon A; Horwich A
    Ann Oncol; 2008 Jul; 19(7):1312-1319. PubMed ID: 18356139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relapse and late complications in early-stage Hodgkin's disease patients with mediastinal involvement treated with radiotherapy alone or plus one cycle of ABVD.
    Enrici RM; Anselmo AP; Donato V; Falchetto Osti M; Santoro M; Tombolini V; Mandelli F
    Haematologica; 1999 Oct; 84(10):917-23. PubMed ID: 10509040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose therapy autologous stem cell transplantation vs conventional therapy for patients with advanced Hodgkin's disease responding to first-line therapy: analysis of clinical characteristics of 51 patients enrolled in the HD01 protocol. EBMT/ANZLG/Intergroup HD01 Trial.
    Federico M; Clò V; Carella AM
    Leukemia; 1996 Jun; 10 Suppl 2():s69-71. PubMed ID: 8649056
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Standard therapy of advanced Hodgkin lymphoma.
    Kuruvilla J
    Hematology Am Soc Hematol Educ Program; 2009; ():497-506. PubMed ID: 20008235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose chemotherapy and autologous stem cell transplantation for primary refractory or relapsed Hodgkin lymphoma: long-term outcome in the first 100 patients treated in Vancouver.
    Lavoie JC; Connors JM; Phillips GL; Reece DE; Barnett MJ; Forrest DL; Gascoyne RD; Hogge DE; Nantel SH; Shepherd JD; Smith CA; Song KW; Sutherland HJ; Toze CL; Voss NJ; Nevill TJ
    Blood; 2005 Aug; 106(4):1473-8. PubMed ID: 15870180
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term overall survival and toxicities of ABVD vs BEACOPP in advanced Hodgkin lymphoma: A pooled analysis of four randomized trials.
    André MPE; Carde P; Viviani S; Bellei M; Fortpied C; Hutchings M; Gianni AM; Brice P; Casasnovas O; Gobbi PG; Zinzani PL; Dupuis J; Iannitto E; Rambaldi A; Brière J; Clément-Filliatre L; Heczko M; Valagussa P; Douxfils J; Depaus J; Federico M; Mounier N
    Cancer Med; 2020 Sep; 9(18):6565-6575. PubMed ID: 32710498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High-dose chemotherapy and peripheral hematopoietic stem cell transplantation in relapsed/refractory Hodgkin's lymphoma.
    Kelta M; Zekri J; Abdelghany E; Rehman JU; Khan ZA; Al-Saadi R; Dada R
    Tumori; 2018 Dec; 104(6):471-475. PubMed ID: 28009428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group.
    Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Bezjak A; Wells WA; Burns BF; Winter JN; Horning SJ; Dar AR; Djurfeldt MS; Ding K; Shepherd LE; ;
    J Clin Oncol; 2005 Jul; 23(21):4634-42. PubMed ID: 15837968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Results of treatment with doxorubicin, bleomycin, vinblastine and dacarbazine and highly active antiretroviral therapy in advanced stage, human immunodeficiency virus-related Hodgkin's lymphoma.
    Xicoy B; Ribera JM; Miralles P; Berenguer J; Rubio R; Mahillo B; Valencia ME; Abella E; López-Guillermo A; Sureda A; Morgades M; Navarro JT; Esteban H; ;
    Haematologica; 2007 Feb; 92(2):191-8. PubMed ID: 17296568
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival analysis of patients with Hodgkin lymphoma who failed high dose chemotherapy and autologous stem cell transplant.
    Elshenawy MA; Shahzad Rauf M; Elhassan TAM; Maghfoor I; Akhtar S
    Ann Hematol; 2018 Jul; 97(7):1229-1240. PubMed ID: 29484455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ABVD alone versus radiation-based therapy in limited-stage Hodgkin's lymphoma.
    Meyer RM; Gospodarowicz MK; Connors JM; Pearcey RG; Wells WA; Winter JN; Horning SJ; Dar AR; Shustik C; Stewart DA; Crump M; Djurfeldt MS; Chen BE; Shepherd LE; ;
    N Engl J Med; 2012 Feb; 366(5):399-408. PubMed ID: 22149921
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
    Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
    Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.